Umeoka F.,Saiseikai Matusuyama Hospital |
Miyaoka H.,Saiseikai Matusuyama Hospital |
Oka Y.,Saiseikai Matusuyama Hospital |
Inada N.,Saiseikai Matusuyama Hospital |
Okada T.,Saiseikai Matusuyama Hospital
Journal of the Japan Diabetes Society | Year: 2010
The frequency of hepatocellular carcinoma (HCC) with underlying nonalcoholic steatohepatitis (NASH) is increasing, and insulin resistance due to underlying obesity and diabetes is suspected of playing a role in hepatic carcinogenesis. This study divided 80 patients with type 2 diabetes and coexisting chronic liver disease into patients with HCC (n = 36) and without HCC (n = 44), then compared insulin resistance and frequency of use of insulin and oral hypoglycemic agents (insulin secretion-stimulating drugs, and metformin). Fasting serum insulin was 14.5 ± 5.5 μ U/m/ in the HCC group and 8.65 ± 5.0 μ U/ml in the non-HCC group. The homeostasis model assessment-insulin resistance index was 4.34 ± 1.74 in the HCC group and 2.53 ± 1.21 in the nonHCC group. In both cases, values were significantly higher in the HCC group (P < 0.05). In addition, the frequency of metformin use was significantly lower in the HCC group than in the non-HCC group. This suggests that treatment of insulin resistance with metformin may reduce the incidence of HCC.